Stay updated on NSCLC Carboplatin+Pemetrexed+Bevacizumab+/-Atezolizumab Clinical Trial

Sign up to get notified when there's something new on the NSCLC Carboplatin+Pemetrexed+Bevacizumab+/-Atezolizumab Clinical Trial page.
Latest website image capture
Clouds background image

Latest updates to the NSCLC Carboplatin+Pemetrexed+Bevacizumab+/-Atezolizumab Clinical Trial page

  1. Check
    5 days ago
    No Change Detected
  2. Check
    12 days ago
    Change Detected
    Summary
    The expected modernization date for the ClinicalTrials.gov data ingest has been updated from June 2025 to July 2025.
    Difference
    0.6%
    Check dated 2025-06-19T19:35:10.000Z thumbnail image
  3. Check
    19 days ago
    No Change Detected
  4. Check
    27 days ago
    Change Detected
    Summary
    The web page has been updated from version 2.16.1 to version 2.16.2.
    Difference
    0.1%
    Check dated 2025-06-05T11:11:26.000Z thumbnail image
  5. Check
    34 days ago
    Change Detected
    Summary
    The web page has been updated to indicate that the ClinicalTrials.gov data ingest will be modernized in June 2025, allowing API users to provide input before implementation. Additionally, the revision number has been updated from v2.15.2 to v2.16.1.
    Difference
    1%
    Check dated 2025-05-29T05:55:41.000Z thumbnail image
  6. Check
    63 days ago
    Change Detected
    Summary
    The web page has been updated from version 2.15.0 to version 2.15.2.
    Difference
    0.1%
    Check dated 2025-04-30T13:58:14.000Z thumbnail image
  7. Check
    70 days ago
    Change Detected
    Summary
    The webpage has updated its contact information, replacing Dr. Joseph Treat with Dr. Joseph Bodor, including new phone numbers and email addresses. Additionally, the dates have been updated to reflect the current timeline.
    Difference
    0.9%
    Check dated 2025-04-23T08:37:24.000Z thumbnail image
  8. Check
    77 days ago
    Change Detected
    Summary
    The webpage has undergone significant updates, including the addition of a new interventional model description for a clinical trial involving non-small cell lung cancer, and the removal of extensive background information on lung cancer treatment and patient eligibility criteria.
    Difference
    66%
    Check dated 2025-04-16T02:11:23.000Z thumbnail image

Stay in the know with updates to NSCLC Carboplatin+Pemetrexed+Bevacizumab+/-Atezolizumab Clinical Trial

Enter your email address, and we'll notify you when there's something new on the NSCLC Carboplatin+Pemetrexed+Bevacizumab+/-Atezolizumab Clinical Trial page.